FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response:

0.5

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addr Epperly Mel	ess of Reporting Person <sup>*</sup> <u>issa B,</u>	2. Date of Event Requi Statement (Month/Day, 06/09/2021		3. Issuer Name and Ticker or Trading Symbol Nautilus Biotechnology, Inc. [ NAUT ]							
	(First) JS BIOTECHNOLOG AVE N, STE 202 WA (State)	(Middle) GY, INC. 98109 (Zip)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)		y below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)   X Form filed by One Reporting Person   Form filed by More than One Reporting Person			
			Table I -	Non-Deriv	' vative S	ecurities Beneficially Ow	ned				
1. Title of Security (Instr. 4)					2. Amount Owned (Ins	of Securities Beneficially str. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)		
						urities Beneficially Owne options, convertible secu					
1. Title of Derivative Security (Instr. 4)			Expiration D	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlyin Security (Instr. 4)		4. Convers or Exerc	sion I sise (	or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares		ve  '	(Instr. 5)	
Stock Option (Right to Buy)			(1)	01/31/2031		Common Stock	72,561			D	

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan (the "Plan")) through each vesting date, one thirty-sixth (1/36th) of the shares subject to the Option shall vest each month over the thirty-six (36) months following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 31, 2021.

Remarks:

Exhibit 24: Power of Attorney

/s/ Anna Mowry, as Attorney-in-Fact 06/09/2021 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Nautilus Biotechnology, Inc. (the "Company"), hereby constitutes and appoints Sujal Patel 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion det 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national assoc: The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The under This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of June, 2021.

Signature: /s/ Melissa Epperly

Print Name: Melissa Epperly